FIELD: molecular immunology; biotechnology; molecular diagnostics; medicine.
SUBSTANCE: bacterial producer of a new polypeptide, which is a recombinant derivative of the antigen-recognition domain of a special camel antibody that does not have light chains, has been obtained. The resulting polypeptide (nanobody) has the ability to effectively recognize and bind the conserved region of the receptor-binding domain of the surface protein (Spike) of the pandemic coronavirus SARS-CoV-2.
EFFECT: such a polypeptide, which is a single-domain antibody, in addition to traditional use in immunoassays and diagnostics, can be used to develop combined new medicinal products as a module for target-specific binding and delay/blocking of coronavirus in the human upper respiratory tract.
3 cl, 7 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-DOMAIN LLAMA ANTIBODY H5 AND ITS DERIVATIVE H5-Fc SPECIFICALLY BINDING THE RBD DOMAIN OF THE S-PROTEIN OF THE SARS-CoV-2 VIRUS POSSESSING VIRUS-NEUTRALIZING ACTIVITY | 2022 |
|
RU2793967C1 |
| MONOCLONAL ANTIBODY IC1 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817696C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| SINGLE-DOMAIN NANO-ANTIBODIES AGAINST SPIKE PROTEIN OF SARS-CoV-2 VIRUS | 2021 |
|
RU2794141C2 |
| BROADLY NEUTRALIZING ANTIBODY AGAINST SARS-CoV-2 | 2022 |
|
RU2810476C1 |
| BISPECIFIC MONOCLONAL ANTIBODY AGAINST SARS-COV-2 | 2022 |
|
RU2791749C1 |
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| HUMANIZED MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO RBD S OF THE PROTEIN OF THE SARS-COV-2 VIRUS, AGENT AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS-COV-2 VIRUS | 2021 |
|
RU2765731C1 |
| MONOCLONAL ANTIBODY TO RDB FRAGMENT IN COMPOSITION OF SARS-COV-2 S PROTEIN | 2020 |
|
RU2744274C1 |
